Bayer AG divests plasma unit
This article was originally published in The Gray Sheet
German firm's restructuring to focus on high-performance diagnostic systems, consumer health and pharmaceuticals includes divestiture of plasma business, which makes drugs. Newly formed NPS BioTherapeutics, backed by Cerberus Capital and Ampersand Ventures, will buy the unit for $590 mil. under a Dec. 13 deal...
You may also be interested in...
EU Regulatory Roundup, February 2020: Brexit And Swixit Threaten Huge Disruption Amidst MDR Uncertainty
Complying with the EU’s new Medical Device Regulation would be hard enough. But more layers of uncertainty – especially Brexit and Swixit ̶ mean European medtech is navigating very turbulent waters right now.
Fresenius Kabi has reported sales ahead by 6% in 2019, as growth in emerging markets helped to offset a subdued increase in North America. Meanwhile, the firm has pushed back financial expectations for its biosimilars by a year.
Fresenius Kabi and Vifor Pharma have agreed to create a joint venture in China for intravenous iron products.